| Name | Title | Contact Details |
|---|
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.
Fifth Eye`s early warning system continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods.
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.
Intrigma is a leader in medical scheduling solutions that deliver bottom-line impact to medical groups, hospitals and hospital systems.
Igentify® is a digital health company. We help clinicians, laboratories, and patients access, interpret, and use genetic information and education more effectively. Igentify developed the world`s first Digital Genetic Assistant, a software-based decision support platform. Our platform is capable of providing a fully scalable end-to-end genetic counseling solution in both clinical as well as non-clinical (direct-to-consumer) genetic testing set up. The platform is built for various genotyping technologies like microarray and next-generation sequencing (NGS). It can be customized to a broad spectrum of genetic and genomic tests offered by the test providers. Founded in Oct. 2016, Igentify`s team of globally renowned geneticists, highly experienced software developers, creative animators, and UX/UI designers, is redefining the protocols of traditional medicine. In Jan. 2019, Deloitte selected Igentify as one of the Israeli startups at the forefront of the Digital R&D Revolution.